What Next for Apricus Biosciences Inc (NASDAQ:APRI) Stock After Decrease in Shorted Shares?

October 2, 2018 - By Hugh Holland

The stock of Apricus Biosciences Inc (NASDAQ:APRI) registered a decrease of 2.54% in short interest. APRI’s total short interest was 1.14 million shares in October as published by FINRA. Its down 2.54% from 1.17M shares, reported previously. With 415,000 shares average volume, it will take short sellers 3 days to cover their APRI’s short positions.

The stock decreased 5.84% or $0.0216 during the last trading session, reaching $0.3484. About 692,846 shares traded or 15.16% up from the average. Apricus Biosciences, Inc. (NASDAQ:APRI) has declined 82.06% since October 2, 2017 and is downtrending. It has underperformed by 97.68% the S&P500.

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. The company has market cap of $8.17 million. The Company’s lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. It currently has negative earnings. The firm also engages in developing RayVa, which is in Phase 2 development for the treatment of RaynaudÂ’s Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>